Novo Nordisk launches weightloss drug Wegovy in India at competitive prices, facing patent battles and high demand.

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

FAT jabs are shrinking supermarket sales, with grocery volumes falling 0.4% year-on-year, new figures reveal. Popular Ozempic ...

NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.

With the weight-loss blockbuster drug Wegovy, now in India, renowned endocrinologist and diabetologist Dr. Ambrish Mithal ...

Novo Nordisk launches Wegovy in India, expanding GLP-1 obesity drug market. The product competes with Eli Lilly's Mounjaro ...

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's Mounjaro, which gained early traction. Both drugs address rising obesity and ...

Mounjaro has been approved for both type 2 diabetes and weight loss, but access will be limited by strict eligibility ...

Boots Online Doctor has revealed the 'very common' side-effects of Mounjaro you need to know about after thousands of people ...

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

Weaver outlined her concerns with counterfeit weight-loss medication. “If there is, contaminants, allergens in it, that sort ...